RayzeBio Appoints Industry Leader Tim Van Hauwermeiren to Its Board of Directors
November 01 2023 - 5:00AM
RayzeBio, Inc. (Nasdaq: RYZB), a targeted radiopharmaceutical
company developing an innovative pipeline against validated solid
tumor targets, today announced the appointment of Tim Van
Hauwermeiren to its board of directors. As co-founder and CEO of
argenx, Tim has built a reputation for his strong execution and
innovation, leading argenx from early-stage development into a
global immunology company.
“RayzeBio has the potential to transform the oncology treatment
landscape through targeted radiopharmaceuticals. I see a lot of
parallels between RayzeBio and argenx and look forward to
leveraging my experience to help RayzeBio unlock the full potential
of this emerging modality,” said Tim.
Tim Van Hauwermeiren co-founded argenx and has served as Chief
Executive Officer since 2008. Tim has more than 20 years of general
management and business development experience across the life
sciences and consumer goods sectors, including at Ablynx and
Procter & Gamble. He holds a B.Sc. and M.Sc. in bioengineering
from Ghent University and an Executive MBA from The Vlerick School
of Management. Tim serves on the Board of Directors of iTeos
Pharmaceuticals.
“I am thrilled to welcome Tim to our board of directors,” said
Ken Song, M.D., President and CEO of RayzeBio. “He has been a major
force in scaling argenx from a small private company to a global
commercial organization bringing forth innovative medicines to help
patients. His perspective as a successful operator can help inform
us as we continue to build and maintain our leadership in
radiopharmaceuticals.”
In connection with Tim joining the board of directors, Aaron
Royston, M.D. has resigned as a board member, effective
November 1, 2023. Dr. Royston served as a director of the company
from August 2020.
“RayzeBio has made tremendous progress in a very short
timeframe. I look forward to staying engaged as an investor and
continuing to see the company flourish,” said Dr. Royston.
Dr. Royston indicated that his resignation was not a result of
any disagreement with the company on any matter relating to the
company's operations, policies or practices.
About RayzeBioRayzeBio is building a vertically
integrated radiopharmaceutical therapeutics (RPT) company to treat
various cancers, with its lead program in a Phase 3 clinical trial.
RayzeBio has created a pipeline of multiple drug candidates in
therapeutic areas with significant market opportunities. Much like
antibody drug conjugates emerged as a new and transformative
treatment modality in certain cancers, the company sees an
opportunity for innovative radiopharmaceutical therapeutics to
follow a similar path. RayzeBio believes its strategic investments
in building a robust product pipeline, development capabilities,
and manufacturing infrastructure position the company to be an
industry-leading pioneer in the broad application of RPT for
cancer.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Statements in
this press release that are not statements of historical fact are
forward-looking statements. Such forward-looking statements
include, without limitation, statements regarding the company's
potential to transform the oncology treatment landscape through
targeted radiopharmaceuticals, and to build and maintain a
leadership position in radiopharmaceuticals. Words such as
“believe,” “anticipate,” “plan,” “expect,” “intend,” “will,” “may,”
“goal,” “potential” and similar expressions are intended to
identify forward-looking statements, though not all forward-looking
statements necessarily contain these identifying words. These
forward-looking statements are based on the beliefs of the
management of the company as well as assumptions made by and
information currently available to the company. Such statements
reflect the current views of the company with respect to future
events and are subject to known and unknown risks and
uncertainties, including business, regulatory, economic and
competitive risks and uncertainties about the company, including,
without limitation, risks inherent in developing drug candidates,
future results from the company’s ongoing and planned clinical
trials, the company’s ability to obtain adequate financing to fund
its planned clinical trials and other expenses, risks that future
clinical trial results may not be consistent with interim, initial
or preliminary results or results from prior preclinical studies or
clinical trials, trends in the industry, the legal and regulatory
framework for the industry and future expenditures. In light of
these risks and uncertainties, the events or circumstances referred
to in the forward-looking statements may not occur. The actual
results may vary from the anticipated results and the variations
may be material. Other factors that may cause the company’s actual
results to differ from current expectations are discussed in the
company’s filings with the Securities and Exchange Commission (the
“SEC”), including the section titled “Risk Factors” in the
company’s Registration Statement on Form S-1 filed with the SEC on
September 11, 2023. You are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the
date this press release is given. Except as required by law, the
company undertakes no obligation to publicly update any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Contact: Arvind
KushEmail: info@rayzebio.com
RayzeBio (NASDAQ:RYZB)
Historical Stock Chart
From May 2024 to Jun 2024
RayzeBio (NASDAQ:RYZB)
Historical Stock Chart
From Jun 2023 to Jun 2024